Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2013 1
2015 2
2016 2
2017 3
2018 1
2019 2
2020 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Predictive markers of safety and immunogenicity of adjuvanted vaccines.
Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B. Mastelic B, et al. Biologicals. 2013 Nov;41(6):458-68. doi: 10.1016/j.biologicals.2013.08.006. Epub 2013 Sep 23. Biologicals. 2013. PMID: 24071553
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been included in vaccine preparations to boost the immune responses through different mechanisms. ...This report reflects the conclusions of a
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been inclu
Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.
Doubovetzky M, Ataman-Önal Y, Chousterman B, Feroldi E, Garçon N, Grillet MH, Kramer D, Laurent S, Lewis DJM, Luna E, Manigold T, Syntin P, Burdin N, Fraisse L, Jackson N. Doubovetzky M, et al. Vaccine. 2020 Dec 3;38(51):8055-8063. doi: 10.1016/j.vaccine.2020.10.015. Epub 2020 Nov 10. Vaccine. 2020. PMID: 33187767
State-of-the art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics …
State-of-the art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes …
Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.
Sasaki E, Asanuma H, Momose H, Furuhata K, Mizukami T, Hamaguchi I. Sasaki E, et al. Front Immunol. 2020 Sep 11;11:2171. doi: 10.3389/fimmu.2020.02171. eCollection 2020. Front Immunol. 2020. PMID: 33013912 Free PMC article.
The efficacy of vaccine adjuvants depends on their ability to appropriately enhance the immunogenicity of vaccine antigens, which is often insufficient in non-adjuvanted vaccines. Genomic analyses of immune responses elicited by …
The efficacy of vaccine adjuvants depends on their ability to appropriately enhance the immunogenicity of vaccine
Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A, Mavroudis D. Matikas A, et al. Future Oncol. 2015;11(6):997-1009. doi: 10.2217/fon.14.287. Future Oncol. 2015. PMID: 25760979 Review.
Unfortunately, although response rates are high, disease progression is universal. Despite the success of IL-2 and adjuvant IFL-alpha2b, these two agents remained the only approved immunotherapy approaches. ...However, the potential adverse events, the optimal use of these …
Unfortunately, although response rates are high, disease progression is universal. Despite the success of IL-2 and adjuvant IFL-alpha …
Immunotherapies in Early and Advanced Renal Cell Cancer.
Kasenda B, Larkin J, Gore M. Kasenda B, et al. Prog Tumor Res. 2015;42:1-10. doi: 10.1159/000436988. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376844 Review.
Vaccines have continued to be investigated in advanced and adjuvant settings. ...In this chapter we will summarise selected studies on immunotherapy in advanced RCC with a focus on anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies. We will also touch briefly on the
Vaccines have continued to be investigated in advanced and adjuvant settings. ...In this chapter we will summarise selected st
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. Nakajima M, et al. Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. doi: 10.1007/s00262-020-02518-7. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219501 Free PMC article. Clinical Trial.
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant comb …
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel …
A library of recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and reverse vaccinology.
Elton CM, Rodriguez M, Ben Mamoun C, Lobo CA, Wright GJ. Elton CM, et al. Int J Parasitol. 2019 Feb;49(2):115-125. doi: 10.1016/j.ijpara.2018.10.003. Epub 2018 Oct 24. Int J Parasitol. 2019. PMID: 30367868 Free PMC article.
The recent sequencing of the B. microti genome has revealed many novel genes encoding proteins that can now be tested for their suitability as subunit vaccine candidates and diagnostic serological markers. Extracellular proteins are considered excellent vaccine
The recent sequencing of the B. microti genome has revealed many novel genes encoding proteins that can now be tested for their suitability …
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P. Saiag P, et al. Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502712 Free PMC article. Clinical Trial.
There was one complete response (GS-) and two partial responses (GS+). The MAGE-A3 immunotherapeutic was similarly immunogenic in both populations and had a clinically acceptable safety profile. ...Investigation of a GS to predict clinical benefit to adjuv
There was one complete response (GS-) and two partial responses (GS+). The MAGE-A3 immunotherapeutic was similarly immunogenic in bot …
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML. Salazar LG, et al. JAMA Oncol. 2017 Jul 1;3(7):969-973. doi: 10.1001/jamaoncol.2016.6007. JAMA Oncol. 2017. PMID: 28114604 Free PMC article. Clinical Trial.
Albumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1, 8, and 15, and repeated every 28 days over the 12-week period. MAIN OUTCOMES AND MEASURES: The primary endpoint was safety and ORR. Secondary endpoints included the generation of tumor-infiltrating lym …
Albumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1, 8, and 15, and repeated every 28 days over the 12-week period. MAIN …
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Pavlick A, et al. Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7. Cancer Immunol Res. 2020. PMID: 31699709 Free PMC article. Clinical Trial.
Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has no …
Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vacc
16 results